According to Axon Enterprise 's latest financial reports the company's current revenue (TTM) is $1.56 B. In 2022 the company made a revenue of $1.18 B an increase over the years 2021 revenue that were of $0.86 B.The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Year | Revenue | Change |
---|---|---|
2023 (TTM) | $1.56 B | 31.38% |
2022 | $1.18 B | 37.82% |
2021 | $0.86 B | 26.78% |
2020 | $0.68 B | 28.28% |
2019 | $0.53 B | 26.37% |
2018 | $0.42 B | 22.18% |
2017 | $0.34 B | 28.17% |
2016 | $0.26 B | 35.55% |
2015 | $0.19 B | 20.28% |
2014 | $0.16 B | 19.37% |
2013 | $0.13 B | 20.11% |
2012 | $0.11 B | 27.46% |
2011 | $90.02 M | 3.56% |
2010 | $86.93 M | -16.62% |
2009 | $0.10 B | 12.29% |
2008 | $92.84 M | -7.82% |
2007 | $0.10 B | 48.75% |
2006 | $67.71 M | 41.98% |
2005 | $47.69 M | -29.49% |
2004 | $67.63 M | 176.58% |
2003 | $24.45 M | 148.46% |
2002 | $9.84 M | 43.62% |
2001 | $6.85 M |
Company | Revenue | Revenue differencediff. | Country |
---|---|---|---|
XBiotech XBIT | N/A | N/A | ๐บ๐ธ USA |
Sangamo Therapeutics
SGMO | $0.17 B | -88.73% | ๐บ๐ธ USA |
Flexion Therapeutics
FLXN | $0.10 B | -93.58% | ๐บ๐ธ USA |
Exelixis EXEL | $1.83 B | 17.07% | ๐บ๐ธ USA |